Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0AEOMQ
ADC Name
Biolegend (#363101)-MDpr-PEG (12)-gluc-MMAE
Synonyms
Biolegend (#363101)-MDpr-PEG (12)-gluc-MMAE
   Click to Show/Hide
Organization
SEAGEN INC.
Drug Status
Investigative
Drug-to-Antibody Ratio
8
Structure
Antibody Name
Biolegend (#363101)
  Antibody Info 
Antigen Name
Melanotransferrin (MELTF)
  Antigen Info 
Payload Name
Monomethyl auristatin E
  Payload Info 
Therapeutic Target
Microtubule (MT)
  Target Info 
Linker Name
MDpr-PEG (12)gluc
  Linker Info 
Conjugate Type
Random conjugation through reduced inter-chain cysteines.
Combination Type
MDpr-PEG (12)gluc-MMAE
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Click To Hide/Show 5 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Half Maximal inhibitory Concentration (lC50) 
2
nM
CVCL_1666
Malignant melanoma
Half Maximal inhibitory Concentration (lC50) 
7
nM
CVCL_0527
Cutaneous melanoma
Half Maximal inhibitory Concentration (lC50) 
100
nM
CVCL_0527
Cutaneous melanoma
Half Maximal inhibitory Concentration (lC50) 
718
nM
CVCL_1059
Melanoma
Half Maximal inhibitory Concentration (lC50) 
> 1000
nM
CVCL_1666
Malignant melanoma
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
Click To Hide/Show 5 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50)
2 nM
Method Description
Tumor cells (RPMI-7951+p97) were incubated with CD228 ADCs for 96-144 hours at 37°C. Cell viability was measured using Cell Titer Glo according to manufacturer'sinstructions.
In Vitro Model Malignant melanoma RPMI-7951 cells CVCL_1666
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50)
7 nM
Method Description
Tumor cells (SK-MEL-28) were incubated with CD228 ADCs for 96-144 hours at 37°C. Cell viability was measured using Cell Titer Glo according to manufacturer'sinstructions.
In Vitro Model Cutaneous melanoma SK-MEL-5 cells CVCL_0527
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50)
100 nM
Method Description
Tumor cells (SK-MEL-5) were incubated with CD228 ADCs for 96-144 hours at 37°C. Cell viability was measured using Cell Titer Glo according to manufacturer'sinstructions.
In Vitro Model Cutaneous melanoma SK-MEL-5 cells CVCL_0527
Experiment 4 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50) 718 nM Moderate MELTF expression (MELTF++)
Method Description
Tumor cells (A2058) were incubated with CD228 ADCs for 96-144 hours at 37°C. Cell viability was measured using Cell Titer Glo according to manufacturer'sinstructions.
In Vitro Model Melanoma A2058 cells CVCL_1059
Experiment 5 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50) > 1000 nM
Method Description
Tumor cells (RPMI-7951) were incubated with CD228 ADCs for 96-144 hours at 37°C. Cell viability was measured using Cell Titer Glo according to manufacturer'sinstructions.
In Vitro Model Malignant melanoma RPMI-7951 cells CVCL_1666
References
Ref 1 Anti-CD228 antibodies and antibody-drug conjugates